腹泻型肠易激综合征(irritable bowel syndrome with diarrhoea,IBS-D)是最常见的消化系统疾病之一,发病机制复杂,临床表现个体差异性大。目前西药主要是对症治疗,但仍存在停药后反复发作等弊端。中药治疗IBS-D辨证施治,疗效显著。IBS-...腹泻型肠易激综合征(irritable bowel syndrome with diarrhoea,IBS-D)是最常见的消化系统疾病之一,发病机制复杂,临床表现个体差异性大。目前西药主要是对症治疗,但仍存在停药后反复发作等弊端。中药治疗IBS-D辨证施治,疗效显著。IBS-D属于中医学“肠郁”“腹痛”“泄泻”等范畴,病变部位主要在肝脾。中医药疏肝健脾方法治疗IBS-D从改善脾胃功能、调节情志出发,对肝郁脾虚型IBS-D腹痛腹泻等临床症状疗效确切,其中以痛泻要方为代表。痛泻要方能够缓解肠肌痉挛导致的腹痛,改善腹泻的症状;且具有降低IBS-D模型大鼠的内脏高敏感、改善免疫功能、调节脑肠肽等作用。近几年的研究表明痛泻要方对改善肠道菌群失调、降低肠道通透性以及表观遗传等方面亦有影响。该文章全面综述了目前关于痛泻要方治疗IBS-D作用机制,为经方治疗IBS-D提供最新的理论依据。展开更多
Background:Irritable bowel syndrome(IBS)is a chronic functional bowel disorder characterized by abdominal pain and altered bowel function.The TongXieYaoFang(TXYF)is a Chinese herbal formula with a long history for the...Background:Irritable bowel syndrome(IBS)is a chronic functional bowel disorder characterized by abdominal pain and altered bowel function.The TongXieYaoFang(TXYF)is a Chinese herbal formula with a long history for the management of chronic diarrhea accompanied by abdominal pain,and it is always used to relieve symptoms of IBS.Although there are some studies were published,there is no consensus on its effects.Moreover,new relevant study was published recently.Therefore,a systematic review and meta-analysis is needed to assess the safety and eff ectiveness of the Chinese herbal medicine TongXieYaoFang for IBS.Methods and analysis:PubMed,EMBASE,the Cochrane library,CNKI,WanFang,VIP and CBM databases will be searched without search date and language restrictions.We will include randomized controlled trial(RCT)comparing TXYF with another therapy method for IBS.The quality of included studies will be independently assessed using Risk of bias tool in the Cochrane Handbook 5.1.0,and be categorized as being at low,unclear or high risk of bias.The primary outcome is the disappearance and significant improvement in global symptoms,and the secondary outcomes including visual analog scale(VAS)score,adverse event,rehospitalization rate and the quality of life.The Meta-analysis will be performed using the Cochrane Collection’s tool RevMan 5.3 software.Results:This study is ongoing and will be submitted to a peerreviewed journal for publication.Conclusion:This study will provide a confirmed evidence on the safety and eff ectiveness of TXYF for IBS.Ethics and dissemination:Ethical approval and patient consent are not required because of the study is a systematic review and meta-analysis based on literatures.The results of this study will be submitted to a peer-reviewed journal for publication.展开更多
文摘腹泻型肠易激综合征(irritable bowel syndrome with diarrhoea,IBS-D)是最常见的消化系统疾病之一,发病机制复杂,临床表现个体差异性大。目前西药主要是对症治疗,但仍存在停药后反复发作等弊端。中药治疗IBS-D辨证施治,疗效显著。IBS-D属于中医学“肠郁”“腹痛”“泄泻”等范畴,病变部位主要在肝脾。中医药疏肝健脾方法治疗IBS-D从改善脾胃功能、调节情志出发,对肝郁脾虚型IBS-D腹痛腹泻等临床症状疗效确切,其中以痛泻要方为代表。痛泻要方能够缓解肠肌痉挛导致的腹痛,改善腹泻的症状;且具有降低IBS-D模型大鼠的内脏高敏感、改善免疫功能、调节脑肠肽等作用。近几年的研究表明痛泻要方对改善肠道菌群失调、降低肠道通透性以及表观遗传等方面亦有影响。该文章全面综述了目前关于痛泻要方治疗IBS-D作用机制,为经方治疗IBS-D提供最新的理论依据。
文摘Background:Irritable bowel syndrome(IBS)is a chronic functional bowel disorder characterized by abdominal pain and altered bowel function.The TongXieYaoFang(TXYF)is a Chinese herbal formula with a long history for the management of chronic diarrhea accompanied by abdominal pain,and it is always used to relieve symptoms of IBS.Although there are some studies were published,there is no consensus on its effects.Moreover,new relevant study was published recently.Therefore,a systematic review and meta-analysis is needed to assess the safety and eff ectiveness of the Chinese herbal medicine TongXieYaoFang for IBS.Methods and analysis:PubMed,EMBASE,the Cochrane library,CNKI,WanFang,VIP and CBM databases will be searched without search date and language restrictions.We will include randomized controlled trial(RCT)comparing TXYF with another therapy method for IBS.The quality of included studies will be independently assessed using Risk of bias tool in the Cochrane Handbook 5.1.0,and be categorized as being at low,unclear or high risk of bias.The primary outcome is the disappearance and significant improvement in global symptoms,and the secondary outcomes including visual analog scale(VAS)score,adverse event,rehospitalization rate and the quality of life.The Meta-analysis will be performed using the Cochrane Collection’s tool RevMan 5.3 software.Results:This study is ongoing and will be submitted to a peerreviewed journal for publication.Conclusion:This study will provide a confirmed evidence on the safety and eff ectiveness of TXYF for IBS.Ethics and dissemination:Ethical approval and patient consent are not required because of the study is a systematic review and meta-analysis based on literatures.The results of this study will be submitted to a peer-reviewed journal for publication.
